Galapagos NV ▲ Sign in to save

• ▲ Bernt van den Blink

  Vicore Pharma (Sweden) Medicine
  3.66k

  citations

  31

  h-index

  5

  Aachen papers
• ▲ Joost H. van den Berg

  The Netherlands Cancer Institute · Galapagos (Netherlands) Immunology and Microbiology
  2.28k

  citations

  22

  h-index

  1

  Aachen papers
• ▲ Robin Besuyen

  Stedelijk Museum Amsterdam Medicine
  1.56k

  citations

  16

  h-index

  37

  Aachen papers
• ▲ Alessandra Faria Oortwijn

  Biochemistry, Genetics and Molecular Biology
  773

  citations

  10

  h-index

  37

  Aachen papers
• ▲ Christine Rudolph

  Biochemistry, Genetics and Molecular Biology
  645

  citations

  12

  h-index

  8

  Aachen papers
• ▲ Mariska C. van der Plas

  Galapagos (Netherlands) Biochemistry, Genetics and Molecular Biology
  220

  citations

  5

  h-index

  1

  Aachen papers
• ▲ Irene Groenveld

  Galapagos (Netherlands) Immunology and Microbiology
  162

  citations

  2

  h-index

  1

  Aachen papers
• ▲ Susan Bellaire

  Galapagos (Netherlands) Pharmacology, Toxicology and Pharmaceutics
  118

  citations

  4

  h-index

  2

  Aachen papers
• ▲ Angela de Haas

  Galapagos (Netherlands) Biochemistry, Genetics and Molecular Biology
  58

  citations

  4

  h-index

  8

  Aachen papers
• ▲ Anna Jus

  Alfasigma (Italy) Biochemistry, Genetics and Molecular Biology
  27

  citations

  3

  h-index

  3

  Aachen papers
• ▲ Virginia Taliadouros

  Galapagos (Netherlands) Biochemistry, Genetics and Molecular Biology
  21

  citations

  2

  h-index

  5

  Aachen papers
• ▲ C Rudolph

  Alfasigma (Italy) Biochemistry, Genetics and Molecular Biology
  15

  citations

  3

  h-index

  7

  Aachen papers
• ▲ T. Hendrikx

  Galapagos (Netherlands) · Galapagos (Belgium) Medicine
  4

  citations

  1

  h-index

  2

  Aachen papers
• ▲ B Eskens

  Galapagos (Netherlands) Biochemistry, Genetics and Molecular Biology
  3

  citations

  1

  h-index

  1

  Aachen papers

14 results

• Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

  2023 JAMA article Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Open access

  141

  citations
• Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial

  2022 The American Journal of Gastroenterology article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access cited by 1 patent

  31

  citations
• Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE

  2023 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  22

  citations
• Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial

  2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  18

  citations
• Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey

  2024 Inflammatory Bowel Diseases article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  16

  citations
• Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

  2022 Intestinal Research article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  15

  citations
• Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study

  2024 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  14

  citations
• Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial

  2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  10

  citations
• ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis

  2023 Clinical Pharmacology & Therapeutics article Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Open access

  10

  citations
• Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies

  2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  7

  citations
• Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study

  2024 Inflammatory Bowel Diseases article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  7

  citations
• Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study

  2024 Inflammatory Bowel Diseases article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access cited by 2 patents

  5

  citations
• Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study

  2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  4

  citations
• POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY

  2022 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

  3

  citations
• P393 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION

  2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  3

  citations
• Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies

  2024 Clinical Pharmacology & Therapeutics article Medicine Drug Transport and Resistance Mechanisms Open access

  3

  citations
• OP35 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study

  2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  3

  citations
• P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme

  2023 Journal of Crohn s and Colitis article Medicine Rheumatoid Arthritis Research and Therapies Open access

  2

  citations
• Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study

  2024 Intestinal Research article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

  2

  citations
• NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy

  2026 Nature Communications article Medicine CAR-T cell therapy research Open access

  1

  citations